The BloodCenter of Wisconsin has launched a next-generation sequencing-based hematological cancer panel, the HemeOne Panel, which is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 myeloid hematologic malignancies. In addition, the BloodCenter of Wisconsin will include a diagnostic report with information about US Food and Drug Administration approved therapies and relevant clinical trials.
Quest Diagnostics has launched BRCAvantage Plus, which screens for mutations in the BRCA1 and BRCA2 genes as well as for mutations in five additional genes: TP53, CDH1, STK11, and PALB2. A key feature of the assay is that physicians can order single gene tests or the full panel. In addition, a "reflex" option automatically tests the five non-BRCA genes when initial BRCA1 and BRCA2 testing is negative.
Enzymatics has launched its Archer FusionPlex FGFR and NTRK panels. The FGFR panel detects known and novel fusions in the FGFR1, FGFR2, and FGFR3 genes. The FGFR genes, fibroblast growth factor receptor genes, are some of the most frequently amplified and mutated genes in cancer and are also promising targets for tyrosine kinase inhibitors, according to the company. The NTKR panel detects gene fusions to NTRK1, NTRK2, and NTRK3, which are found in cancers such as adenocarcinoma, high-grade glioma, pilocytic astrocytoma, and leukemia.
CompanionDx has launched next-generation sequencing-based cancer tests and has partnered with GenomOncology for the clinical report, using the firm's GO Clinical Workbench.
Aperiomics plans to launch Absolute-NGS Pathogen Detection Platform at the Association for Molecular Pathology in November. The platform will include three next-generation sequencing-based assays for pathogen screening. Absolute-ID is designed to detect known pathogens, Absolute-Discovery is designed to detect both known and novel pathogens, while Aboslute-Biome is designed to identify all microorganisms in a given sample.